Supernus Pharma's ADHD drug study met primary endpoint

 

• Supernus Pharmaceuticals (NASDAQ:SUPN) +25.6% post-market after saying a phase 3 study for its SPN-812 drug to treat ADHD in adults met its primary endpoint with "robust statistical significance."
• Supernus says the trial met the primary endpoint in improving the symptoms of ADHD from baseline to end of study as measured by ADHD Investigator Symptom Rating Scale, and the phase 3 study met the key secondary efficacy endpoint with statistical significance.
• The company says SPN-812 already is under review by the U.S. Food and Drug Administration for the treatment of ADHD in pediatric patients age 6-17, and it plans to ask for the drug to be considered for adults as well if it is approved by the FDA.
• Supernus reported more than a month ago that its New Drug Application for SPN-812 was not yet ready for approval, because the company's in-house laboratory that conducts analytical testing had recently moved.
• https://seekingalpha.com/news/3646864-supernus-pharmas-adhd-drug-study-met-primary-endpoint